Cryolife Inc (NYSE:CRY) Director C Elkins Ronald sold 1,000 shares of Cryolife stock in a transaction on Friday, December 15th. The stock was sold at an average price of $20.00, for a total transaction of $20,000.00. Following the sale, the director now directly owns 99,849 shares in the company, valued at approximately $1,996,980. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
C Elkins Ronald also recently made the following trade(s):
- On Monday, November 6th, C Elkins Ronald sold 1,000 shares of Cryolife stock. The stock was sold at an average price of $19.03, for a total transaction of $19,030.00.
Shares of Cryolife Inc (NYSE:CRY) traded down $0.45 on Friday, reaching $19.25. 209,400 shares of the company’s stock traded hands, compared to its average volume of 159,766. Cryolife Inc has a 52 week low of $14.02 and a 52 week high of $24.00. The company has a debt-to-equity ratio of 0.29, a quick ratio of 4.90 and a current ratio of 5.96. The firm has a market cap of $659.11, a PE ratio of 48.05 and a beta of 0.81.
Several hedge funds and other institutional investors have recently bought and sold shares of CRY. First Mercantile Trust Co. raised its holdings in shares of Cryolife by 5.6% during the 2nd quarter. First Mercantile Trust Co. now owns 5,448 shares of the medical equipment provider’s stock worth $109,000 after acquiring an additional 291 shares during the period. Municipal Employees Retirement System of Michigan raised its holdings in shares of Cryolife by 3.7% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 6,380 shares of the medical equipment provider’s stock worth $127,000 after acquiring an additional 230 shares during the period. Victory Capital Management Inc. raised its holdings in shares of Cryolife by 17.7% during the 2nd quarter. Victory Capital Management Inc. now owns 6,937 shares of the medical equipment provider’s stock worth $138,000 after acquiring an additional 1,041 shares during the period. KBC Group NV purchased a new position in shares of Cryolife during the 2nd quarter worth $165,000. Finally, BNP Paribas Arbitrage SA raised its holdings in shares of Cryolife by 67.1% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 8,593 shares of the medical equipment provider’s stock worth $171,000 after acquiring an additional 3,451 shares during the period. Institutional investors and hedge funds own 73.28% of the company’s stock.
CRY has been the topic of several recent research reports. Lake Street Capital lifted their target price on shares of Cryolife to $26.00 and gave the stock a “buy” rating in a research note on Wednesday, October 11th. TheStreet cut shares of Cryolife from a “b” rating to a “c+” rating in a research note on Monday, October 30th. Zacks Investment Research cut shares of Cryolife from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. Northland Securities reaffirmed a “buy” rating and set a $23.50 target price on shares of Cryolife in a research note on Monday, November 13th. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $25.00 target price on shares of Cryolife in a research note on Monday, October 9th. Two analysts have rated the stock with a sell rating and four have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $23.63.
TRADEMARK VIOLATION NOTICE: This story was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://www.com-unik.info/2017/12/22/insider-selling-cryolife-inc-cry-director-sells-20000-00-in-stock.html.
CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.
Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.